Mild Cognitive Impairment Progression and Alzheimer's Disease Risk: A Comprehensive Analysis of 3553 Cases over 203 Months
This study aimed to elucidate the long-term progression of mild cognitive impairment (MCI) within a comprehensive longitudinal dataset, distinguish it from healthy aging, explore the influence of a dementia subtype on this progression, and identify potential contributing factors. Patients with prodr...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical medicine 2024-01, Vol.13 (2), p.518 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 2 |
| container_start_page | 518 |
| container_title | Journal of clinical medicine |
| container_volume | 13 |
| creator | Öksüz, Nevra Ghouri, Reza Taşdelen, Bahar Uludüz, Derya Özge, Aynur |
| description | This study aimed to elucidate the long-term progression of mild cognitive impairment (MCI) within a comprehensive longitudinal dataset, distinguish it from healthy aging, explore the influence of a dementia subtype on this progression, and identify potential contributing factors. Patients with prodromal and preclinical cases underwent regular neuropsychological assessments utilizing various tools. The study included a total of 140 participants with MCI, categorized into Alzheimer's disease (AD) and non-AD subtypes. Our dataset revealed an overall progression rate of 92.8% from MCI to the clinical stage of dementia during the follow-up period, with an annual rate of 15.7%. Notably, all prodromal cases of Lewy body dementia/Parkinson's disease (LBD/PDD) and frontotemporal dementia (FTD) advanced to clinical stages, whereas 7% of vascular dementia (VaD) cases and 8.4% of AD cases remained in the prodromal stage throughout follow-up. Furthermore, we observed a faster progression rate in MCI-AD cases compared to non-AD sufferers (53.9% vs. 35.5%, Entropy: 0.850). This study revealed significant cognitive changes in individuals with MCI over time. The mini-mental state examination (MMSE), global deterioration scale (GDS), and calculation tests were the most effective tests for evaluation of MCI. These findings may offer valuable insights for the development of personalized interventions and management strategies for individuals with MCI. |
| doi_str_mv | 10.3390/jcm13020518 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2917867523</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A780877337</galeid><sourcerecordid>A780877337</sourcerecordid><originalsourceid>FETCH-LOGICAL-c379t-c66ae17b211522b1c91ee366776b97c92374149a36aac4a9a3b4fc6622ecb7873</originalsourceid><addsrcrecordid>eNptkcFvFCEUxonR2Kb25N2QeNDEbAXeDDDeJqvVJm00Rs8Thn2zyzrAFmabtH99GVu1GuHA4-X3ffDyEfKcsxOAhr3dWs-BCVZz_YgcCqbUgoGGxw_qA3Kc85aVpXUluHpKDkCLWspaHJKbCzeu6DKug5vcFdIzvzMueQwT_ZLiOmHOLgZqwoq2480Gncf0KtP3LqPJSL-6_OMdbYuB3yXcYMizSRvMeJ1dpnGgUNdAl4UttytMVDCgFzFMm_yMPBnMmPH4_jwi308_fFt-Wpx__ni2bM8XFlQzLayUBrnqBee1ED23DUcEKZWSfaNsI0BVvGoMSGNsZUrRV0MRCYG2V1rBEXl957tL8XKPeeq8yxbH0QSM-9yJhistVS2goC__Qbdxn8o0PymtFHDO_lBrM2LnwhCnZOxs2rVKsxmD-dmT_1Blr9A7GwMOrvT_Ery5E9gUc044dLvkvEnXHWfdHHb3IOxCv7j_6r73uPrN_ooWbgF_Q6Cl</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2918773110</pqid></control><display><type>article</type><title>Mild Cognitive Impairment Progression and Alzheimer's Disease Risk: A Comprehensive Analysis of 3553 Cases over 203 Months</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>PubMed Central</source><creator>Öksüz, Nevra ; Ghouri, Reza ; Taşdelen, Bahar ; Uludüz, Derya ; Özge, Aynur</creator><creatorcontrib>Öksüz, Nevra ; Ghouri, Reza ; Taşdelen, Bahar ; Uludüz, Derya ; Özge, Aynur</creatorcontrib><description>This study aimed to elucidate the long-term progression of mild cognitive impairment (MCI) within a comprehensive longitudinal dataset, distinguish it from healthy aging, explore the influence of a dementia subtype on this progression, and identify potential contributing factors. Patients with prodromal and preclinical cases underwent regular neuropsychological assessments utilizing various tools. The study included a total of 140 participants with MCI, categorized into Alzheimer's disease (AD) and non-AD subtypes. Our dataset revealed an overall progression rate of 92.8% from MCI to the clinical stage of dementia during the follow-up period, with an annual rate of 15.7%. Notably, all prodromal cases of Lewy body dementia/Parkinson's disease (LBD/PDD) and frontotemporal dementia (FTD) advanced to clinical stages, whereas 7% of vascular dementia (VaD) cases and 8.4% of AD cases remained in the prodromal stage throughout follow-up. Furthermore, we observed a faster progression rate in MCI-AD cases compared to non-AD sufferers (53.9% vs. 35.5%, Entropy: 0.850). This study revealed significant cognitive changes in individuals with MCI over time. The mini-mental state examination (MMSE), global deterioration scale (GDS), and calculation tests were the most effective tests for evaluation of MCI. These findings may offer valuable insights for the development of personalized interventions and management strategies for individuals with MCI.</description><identifier>ISSN: 2077-0383</identifier><identifier>EISSN: 2077-0383</identifier><identifier>DOI: 10.3390/jcm13020518</identifier><identifier>PMID: 38256652</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Advertising executives ; Age ; Alzheimer's disease ; Cognitive ability ; Decision making ; Dementia ; Development and progression ; Disease ; Executive function ; Head injuries ; Medical imaging ; Memory ; Neuroimaging ; Neuropsychology ; Patients ; Problem solving ; Risk factors ; Statistics ; Strategic planning (Business) ; Supervision ; Tomography</subject><ispartof>Journal of clinical medicine, 2024-01, Vol.13 (2), p.518</ispartof><rights>COPYRIGHT 2024 MDPI AG</rights><rights>2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c379t-c66ae17b211522b1c91ee366776b97c92374149a36aac4a9a3b4fc6622ecb7873</cites><orcidid>0000-0003-2797-2398 ; 0000-0001-8146-4912 ; 0009-0003-3630-5674</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27907,27908</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38256652$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Öksüz, Nevra</creatorcontrib><creatorcontrib>Ghouri, Reza</creatorcontrib><creatorcontrib>Taşdelen, Bahar</creatorcontrib><creatorcontrib>Uludüz, Derya</creatorcontrib><creatorcontrib>Özge, Aynur</creatorcontrib><title>Mild Cognitive Impairment Progression and Alzheimer's Disease Risk: A Comprehensive Analysis of 3553 Cases over 203 Months</title><title>Journal of clinical medicine</title><addtitle>J Clin Med</addtitle><description>This study aimed to elucidate the long-term progression of mild cognitive impairment (MCI) within a comprehensive longitudinal dataset, distinguish it from healthy aging, explore the influence of a dementia subtype on this progression, and identify potential contributing factors. Patients with prodromal and preclinical cases underwent regular neuropsychological assessments utilizing various tools. The study included a total of 140 participants with MCI, categorized into Alzheimer's disease (AD) and non-AD subtypes. Our dataset revealed an overall progression rate of 92.8% from MCI to the clinical stage of dementia during the follow-up period, with an annual rate of 15.7%. Notably, all prodromal cases of Lewy body dementia/Parkinson's disease (LBD/PDD) and frontotemporal dementia (FTD) advanced to clinical stages, whereas 7% of vascular dementia (VaD) cases and 8.4% of AD cases remained in the prodromal stage throughout follow-up. Furthermore, we observed a faster progression rate in MCI-AD cases compared to non-AD sufferers (53.9% vs. 35.5%, Entropy: 0.850). This study revealed significant cognitive changes in individuals with MCI over time. The mini-mental state examination (MMSE), global deterioration scale (GDS), and calculation tests were the most effective tests for evaluation of MCI. These findings may offer valuable insights for the development of personalized interventions and management strategies for individuals with MCI.</description><subject>Advertising executives</subject><subject>Age</subject><subject>Alzheimer's disease</subject><subject>Cognitive ability</subject><subject>Decision making</subject><subject>Dementia</subject><subject>Development and progression</subject><subject>Disease</subject><subject>Executive function</subject><subject>Head injuries</subject><subject>Medical imaging</subject><subject>Memory</subject><subject>Neuroimaging</subject><subject>Neuropsychology</subject><subject>Patients</subject><subject>Problem solving</subject><subject>Risk factors</subject><subject>Statistics</subject><subject>Strategic planning (Business)</subject><subject>Supervision</subject><subject>Tomography</subject><issn>2077-0383</issn><issn>2077-0383</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNptkcFvFCEUxonR2Kb25N2QeNDEbAXeDDDeJqvVJm00Rs8Thn2zyzrAFmabtH99GVu1GuHA4-X3ffDyEfKcsxOAhr3dWs-BCVZz_YgcCqbUgoGGxw_qA3Kc85aVpXUluHpKDkCLWspaHJKbCzeu6DKug5vcFdIzvzMueQwT_ZLiOmHOLgZqwoq2480Gncf0KtP3LqPJSL-6_OMdbYuB3yXcYMizSRvMeJ1dpnGgUNdAl4UttytMVDCgFzFMm_yMPBnMmPH4_jwi308_fFt-Wpx__ni2bM8XFlQzLayUBrnqBee1ED23DUcEKZWSfaNsI0BVvGoMSGNsZUrRV0MRCYG2V1rBEXl957tL8XKPeeq8yxbH0QSM-9yJhistVS2goC__Qbdxn8o0PymtFHDO_lBrM2LnwhCnZOxs2rVKsxmD-dmT_1Blr9A7GwMOrvT_Ery5E9gUc044dLvkvEnXHWfdHHb3IOxCv7j_6r73uPrN_ooWbgF_Q6Cl</recordid><startdate>20240101</startdate><enddate>20240101</enddate><creator>Öksüz, Nevra</creator><creator>Ghouri, Reza</creator><creator>Taşdelen, Bahar</creator><creator>Uludüz, Derya</creator><creator>Özge, Aynur</creator><general>MDPI AG</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-2797-2398</orcidid><orcidid>https://orcid.org/0000-0001-8146-4912</orcidid><orcidid>https://orcid.org/0009-0003-3630-5674</orcidid></search><sort><creationdate>20240101</creationdate><title>Mild Cognitive Impairment Progression and Alzheimer's Disease Risk: A Comprehensive Analysis of 3553 Cases over 203 Months</title><author>Öksüz, Nevra ; Ghouri, Reza ; Taşdelen, Bahar ; Uludüz, Derya ; Özge, Aynur</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c379t-c66ae17b211522b1c91ee366776b97c92374149a36aac4a9a3b4fc6622ecb7873</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Advertising executives</topic><topic>Age</topic><topic>Alzheimer's disease</topic><topic>Cognitive ability</topic><topic>Decision making</topic><topic>Dementia</topic><topic>Development and progression</topic><topic>Disease</topic><topic>Executive function</topic><topic>Head injuries</topic><topic>Medical imaging</topic><topic>Memory</topic><topic>Neuroimaging</topic><topic>Neuropsychology</topic><topic>Patients</topic><topic>Problem solving</topic><topic>Risk factors</topic><topic>Statistics</topic><topic>Strategic planning (Business)</topic><topic>Supervision</topic><topic>Tomography</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Öksüz, Nevra</creatorcontrib><creatorcontrib>Ghouri, Reza</creatorcontrib><creatorcontrib>Taşdelen, Bahar</creatorcontrib><creatorcontrib>Uludüz, Derya</creatorcontrib><creatorcontrib>Özge, Aynur</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of clinical medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Öksüz, Nevra</au><au>Ghouri, Reza</au><au>Taşdelen, Bahar</au><au>Uludüz, Derya</au><au>Özge, Aynur</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Mild Cognitive Impairment Progression and Alzheimer's Disease Risk: A Comprehensive Analysis of 3553 Cases over 203 Months</atitle><jtitle>Journal of clinical medicine</jtitle><addtitle>J Clin Med</addtitle><date>2024-01-01</date><risdate>2024</risdate><volume>13</volume><issue>2</issue><spage>518</spage><pages>518-</pages><issn>2077-0383</issn><eissn>2077-0383</eissn><abstract>This study aimed to elucidate the long-term progression of mild cognitive impairment (MCI) within a comprehensive longitudinal dataset, distinguish it from healthy aging, explore the influence of a dementia subtype on this progression, and identify potential contributing factors. Patients with prodromal and preclinical cases underwent regular neuropsychological assessments utilizing various tools. The study included a total of 140 participants with MCI, categorized into Alzheimer's disease (AD) and non-AD subtypes. Our dataset revealed an overall progression rate of 92.8% from MCI to the clinical stage of dementia during the follow-up period, with an annual rate of 15.7%. Notably, all prodromal cases of Lewy body dementia/Parkinson's disease (LBD/PDD) and frontotemporal dementia (FTD) advanced to clinical stages, whereas 7% of vascular dementia (VaD) cases and 8.4% of AD cases remained in the prodromal stage throughout follow-up. Furthermore, we observed a faster progression rate in MCI-AD cases compared to non-AD sufferers (53.9% vs. 35.5%, Entropy: 0.850). This study revealed significant cognitive changes in individuals with MCI over time. The mini-mental state examination (MMSE), global deterioration scale (GDS), and calculation tests were the most effective tests for evaluation of MCI. These findings may offer valuable insights for the development of personalized interventions and management strategies for individuals with MCI.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>38256652</pmid><doi>10.3390/jcm13020518</doi><orcidid>https://orcid.org/0000-0003-2797-2398</orcidid><orcidid>https://orcid.org/0000-0001-8146-4912</orcidid><orcidid>https://orcid.org/0009-0003-3630-5674</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2077-0383 |
| ispartof | Journal of clinical medicine, 2024-01, Vol.13 (2), p.518 |
| issn | 2077-0383 2077-0383 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2917867523 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; PubMed Central |
| subjects | Advertising executives Age Alzheimer's disease Cognitive ability Decision making Dementia Development and progression Disease Executive function Head injuries Medical imaging Memory Neuroimaging Neuropsychology Patients Problem solving Risk factors Statistics Strategic planning (Business) Supervision Tomography |
| title | Mild Cognitive Impairment Progression and Alzheimer's Disease Risk: A Comprehensive Analysis of 3553 Cases over 203 Months |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T11%3A05%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Mild%20Cognitive%20Impairment%20Progression%20and%20Alzheimer's%20Disease%20Risk:%20A%20Comprehensive%20Analysis%20of%203553%20Cases%20over%20203%20Months&rft.jtitle=Journal%20of%20clinical%20medicine&rft.au=%C3%96ks%C3%BCz,%20Nevra&rft.date=2024-01-01&rft.volume=13&rft.issue=2&rft.spage=518&rft.pages=518-&rft.issn=2077-0383&rft.eissn=2077-0383&rft_id=info:doi/10.3390/jcm13020518&rft_dat=%3Cgale_proqu%3EA780877337%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2918773110&rft_id=info:pmid/38256652&rft_galeid=A780877337&rfr_iscdi=true |